Abivax S.A.
obefazimod
ulcerative colitis
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for obefazimod (ulcerative colitis) is expected ~ Dec 31, 2026.
Primary source
· SEC 6-K
verified 14h ago
“The Company plans to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for obefazimod in ulcerative colitis in late Q4 2026”